Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

Abstract EN

Purpose.

To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response.

Design.

Retrospective analysis.

Methods.

Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed.

Results.

At month 3, 14.9% to 29.4% of patients had gained ≥15 letters.

Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment.

After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7–16.1%) than with less frequent dosing (5.0–6.0%).

Monthly dosing also resulted in more patients maintaining VA gains at later time points.

Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted.

Conclusions.

Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment.

Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.